FDA Approves Marketing of Substance Abuse Treatment App

Share this content:
In a 12-week study of 399 patients, 40.3% abstained from further substance use; however, the app is not intended for opioid dependence.
In a 12-week study of 399 patients, 40.3% abstained from further substance use; however, the app is not intended for opioid dependence.

HealthDay News — The US Food and Drug Administration has permitted marketing of the first mobile app to help treat substance use disorders, the agency in a news release.

The Reset application is designed to help treat abuse of alcohol, cocaine, marijuana, and stimulant medications. But the app is not intended for opioid dependence, the FDA said.

The newly-approved app delivers behavioral therapy that's designed to "increase abstinence from substance abuse and increase retention in outpatient therapy programs," the FDA said.

The agency reviewed a 12-week clinical study involving 399 patients.

Among those who used the app, 40.3% abstained from further alcohol, cocaine, marijuana, or stimulant use, compared with 17.6% among those who did not use the app.

Approval of the app was given to Pear Therapeutics, based in Boston and San Francisco.

Follow @ClinicalPainAdv

Reference

FDA permits marketing of mobile medical application for substance use disorder [press release]. US Food and Drug Administration. Updated September 14, 2017. Accessed September 21, 2017. 

You must be a registered member of Clinical Pain Advisor to post a comment.